Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5419]

The 2022 OncoAlert Colloquium Day 1: Breast Cancer

Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden

The 2022 OncoAlert Colloquium Day 1: Breast Cancer ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy...

Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer ( Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA )

HER-Vaxx is safe and provides clinical benefit over standard of care chemo for...

Dr Tanuj Chawla and Dr Giovanni Selvaggi

HER-Vaxx is safe and provides clinical benefit over standard of care chemo for patients with HER2-overexpressing gastric cancer ( Dr Tanuj Chawla and Dr Giovanni Selvaggi )

Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and...

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan

Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and OS in CLDN18.2+/ HER2 mG/GEJ adenocarcinoma ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )

OPERA: Nonoperative modality (NOM) treatments of rectal cancer do not...

Prof Arthur Sun Myint - Clatterbridge Cancer Centre, Clatterbridge, UK

OPERA: Nonoperative modality (NOM) treatments of rectal cancer do not compromise the chance of cure ( Prof Arthur Sun Myint - Clatterbridge Cancer Centre, Clatterbridge, UK )

NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful...

Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan

NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful survival benefit vs chemo for advanced ESCC ( Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan )

The placebo effect in oncology trials and the criteria for approving drugs

Dr Bishal Gyawali - Queen's University, Kingston, Canada

The placebo effect in oncology trials and the criteria for approving drugs ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Breast-conserving therapy may be option for multiple breast lesions

Dr Judy Boughey - Mayo Clinic, Rochester, USA

Breast-conserving therapy may be option for multiple breast lesions ( Dr Judy Boughey - Mayo Clinic, Rochester, USA )

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC

Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San...

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC ( Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

ZUMA-7: Axi-cel is superior to standard of care across common prognostic...

Dr Fred Locke - Moffitt Cancer Center, Tampa, USA

ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL ( Dr Fred Locke - Moffitt Cancer Center, Tampa, USA )

Shorter time from leukapheresis to infusion of axi-cel corresponds to better CR...

Dr Fred Locke - Moffitt Cancer Center, Tampa, USA

Shorter time from leukapheresis to infusion of axi-cel corresponds to better CR and OS in r/r LBCL patients ( Dr Fred Locke - Moffitt Cancer Center, Tampa, USA )

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable...

Dr Ian Krop - Yale Cancer Center, Connecticut, USA

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1 ( Dr Ian Krop - Yale Cancer Center, Connecticut, USA )

More from ecancer